HDAC9 and primary cutaneous T-cell non-Hodgkin lymphoma: Nevertheless, none of these modalities, including the newly introduced agents like retinoids, histone deacetylase (HDAC) inhibitors or pralatrexate have efficiently achieved improvement of survival particularly when it comes to “advanced stage” CTCL patients who still to date suffer a dismal outcome [30].